Lancet Regional Health-Europe最新文献

{"title":"Regional inequalities in heart failure hospitalisation and in-hospital mortality in Spain (2016–2022): a nationwide, observational study","authors":"Carolina Ortiz-Cortés ,&nbsp;Leticia Fernández-Friera ,&nbsp;José M. Gámez ,&nbsp;Ángel Cequier Fillat ,&nbsp;Clara Bonanad Lozano ,&nbsp;Antonia Sambola ,&nbsp;Lorenzo Fácila Rubio ,&nbsp;Luis Rodríguez Padial ,&nbsp;Raquel Campuzano Ruíz ,&nbsp;Milagros Pedreira Pérez ,&nbsp;José M. de la Torre Hernández ,&nbsp;Nicolás Rosillo ,&nbsp;Sofía Sánchez Fernández ,&nbsp;Náyade del Prado ,&nbsp;José Luis Bernal ,&nbsp;Cristina Fernández Pérez ,&nbsp;Diego Alvaredo ,&nbsp;Sergio Rico-Martín ,&nbsp;Francisco Javier Elola-Somoza","doi":"10.1016/j.lanepe.2025.101549","DOIUrl":"10.1016/j.lanepe.2025.101549","url":null,"abstract":"<div><h3>Background</h3><div>Heart failure remains one of the leading causes of hospital admissions and mortality worldwide, with substantial regional disparities in clinical outcomes. These variations have been linked to differences in socioeconomic conditions, health determinants, and health-care system organisation. The aim of this study was to analyse regional differences in hospitalisation rates and in-hospital mortality for heart failure across Spain’s autonomous communities, and to examine their associations with hospital characteristics and regional health determinants.</div></div><div><h3>Methods</h3><div>We conducted a nationwide, retrospective, population-based study using Spain’s national hospital discharge database (Conjunto Mínimo Básico de Datos, CMBD) to identify adults (≥18 years) discharged from public general hospitals within the Spanish National Health System (SNS) with a primary diagnosis of heart failure from January 1, 2016, to December 31, 2022. Differences in hospitalisation rates and risk-standardised in-hospital mortality between autonomous communities were analysed, along with associations with hospital characteristics and regional health determinants.</div></div><div><h3>Findings</h3><div>A total of 764,083 hospitalisations for heart failure were analysed. The mean age of participants was 80.8 ± 10.6 years. The age- and sex-standardised hospitalisation rate was 255 per 100,000 inhabitants, with significant differences between autonomous communities. Crude in-hospital mortality rate was 11.3% (86,426 episodes), with substantial regional variation in risk-standardised mortality rate (ranged from 7.7% to 16.4%) No associations were found between hospital characteristics and risk-standardised mortality rate at the regional level. Regional health determinants were highly collinear; among all determinants assessed, per-capita gross domestic product was independently associated with lower risk-standardised mortality (βGDP_pc = −0.77; 95% CI: −1.04 to −0.49; p &lt; 0.001; R2 = 0.77).</div></div><div><h3>Interpretation</h3><div>Significant regional differences in hospitalisation rates and risk-standardised mortality rates were observed among patients hospitalised for heart failure. Regional disparities in gross domestic product per capita may partly explain these differences. These results have clinical and policy implications, underscoring the need to consider socioeconomic determinants when analysing health outcomes and designing public policies aimed at reducing health inequalities. Our findings might be relevant to other European countries with similar public health systems.</div></div><div><h3>Funding</h3><div>This work was supported by the <span>Spanish Society of Cardiology</span> (Sociedad Española de Cardiología, SEC).</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"61 ","pages":"Article 101549"},"PeriodicalIF":13.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145694036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The burden of dietary risk factors in the Nordic and Baltic countries: a systematic analysis for the Global Burden of Disease Study 2023","authors":"","doi":"10.1016/j.lanepe.2025.101543","DOIUrl":"10.1016/j.lanepe.2025.101543","url":null,"abstract":"<div><h3>Background</h3><div>Detailed knowledge about the disease burden from unhealthy diet in Nordic and Baltic countries is lacking. This study quantifies and compares deaths and disability-adjusted life-years (DALYs) from dietary risks in these countries.</div></div><div><h3>Methods</h3><div>Data from the Global Burden of Disease study 2023 (GBD 2023) was used. Attributable disease burden from 15 dietary risks was analysed using the comparative risk assessment framework. Steps included: (1) estimating dietary intake; (2) assessing relative risks of dietary factors on disease endpoints; (3) determining theoretical minimum risk exposure levels (TMREL); and (4) estimating dietary risk-attributable disease burden as numbers and age-standardised rates (ASR) of deaths and DALYs.</div></div><div><h3>Findings</h3><div>Across the Nordic and Baltic countries (total population = 34,064,020), dietary risks resulted in 38,450 attributed deaths (95% uncertainty interval 10,749–59,386) and 735,284 DALYs (242,417–1,06,638) in 2023. Leading dietary risks included high intake of processed meat and low intake of fruits and whole grains. Dietary risks accounted for 24.9% of cardiovascular disease burden (5.0–37.6), 29.6% of diabetes and kidney disease burden (18.6–40.0), and 7.8% of neoplasm burden (2.9–12.1), with higher burden in the Baltic countries and Greenland than in the Nordic countries.</div></div><div><h3>Interpretation</h3><div>A substantial disease burden can be attributed to dietary risks in the Nordic and Baltic countries. Knowledge about the impact from unhealthy diet can inform targeted public health policies.</div></div><div><h3>Funding</h3><div><span>Gates Foundation and Norwegian Institute of Public Health</span>.</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"61 ","pages":"Article 101543"},"PeriodicalIF":13.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145624593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"20 Years of EU health values (2006–2026): four proposals for the future","authors":"Markus Frischhut ,&nbsp;Barbara Prainsack ,&nbsp;Tamara Hervey ,&nbsp;Anniek de Ruijter ,&nbsp;Tomislav Sokol ,&nbsp;Nick Guldemond ,&nbsp;Joaquin Cayon-De las Cuevas ,&nbsp;André den Exter ,&nbsp;Nick Fahy ,&nbsp;Guerino Massimo Oscar Fares","doi":"10.1016/j.lanepe.2026.101589","DOIUrl":"10.1016/j.lanepe.2026.101589","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"61 ","pages":"Article 101589"},"PeriodicalIF":13.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146037236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-effectiveness of pramipexole augmentation for acute phase and maintenance therapy of treatment-resistant depression compared to placebo augmentation: economic evaluation of the PAX-D randomised controlled trial","authors":"Agata Łaszewska ,&nbsp;Timea Helter ,&nbsp;Ashley Baldwin ,&nbsp;Anthony J. Cleare ,&nbsp;Philip J. Cowen ,&nbsp;Jonathan Evans ,&nbsp;Quentin J.M. Huys ,&nbsp;Micheal Kurkar ,&nbsp;Alexander C. Lewis ,&nbsp;Neil Nixon ,&nbsp;Abhinav Rastogi ,&nbsp;Stuart Watson ,&nbsp;John R. Geddes ,&nbsp;Michael Browning ,&nbsp;Judit Simon","doi":"10.1016/j.lanepe.2025.101533","DOIUrl":"10.1016/j.lanepe.2025.101533","url":null,"abstract":"<div><h3>Background</h3><div>Pramipexole augmentation of antidepressant treatment for treatment-resistant depression (TRD) has been shown to improve symptom burden over 12 weeks but with some adverse effects compared to placebo augmentation. We aimed to evaluate the cost-effectiveness of pramipexole augmentation for TRD.</div></div><div><h3>Methods</h3><div>We conducted an economic evaluation as part of the PAX-D trial over 12 and 48 weeks. Two costing perspectives, National Health Service and Personal Social Services (NHS + PSS) and societal, were adopted. The primary outcome was quality-adjusted life year (QALY) based on the EQ-5D-5L. Secondary outcomes included year of full capability (YFC) based on the ICECAP-A, and capability-weighted life year (CWLY) based on the OxCAP-MH. Incremental cost-effectiveness ratios (ICERs), cost-effectiveness planes and cost-effectiveness acceptability curves were reported alongside sensitivity analyses. The trial was registered with ISCTRN (ISRCTN84666271) and EudraCT (2019-001023-13) and is complete.</div></div><div><h3>Findings</h3><div>From the NHS + PSS perspective, mean incremental cost of pramipexole was £60 (95% CI: −£55, £176) over 12 weeks and £811 (95% CI: £110, £1513) over 48 weeks. The difference in QALY gained was 0.012 (95% CI: 0.003, 0.021) over 12 weeks and 0.090 (95% CI: 0.036, 0.144) over 48 weeks, equivalent to 4 (95% CI: 1, 8) and 33 (95% CI: 13, 52) days in perfect health. The ICER was £5069/QALY (95% CI: −£3642, £35,608) over 12 weeks and £9007/QALY (95% CI: £2,219, £27,258) over 48 weeks, representing over 90% probability of cost-effectiveness at £20,000/QALY threshold. From the societal perspective, pramipexole was on average cost saving and more effective over 48 weeks. Alternative analyses provided consistent conclusions.</div></div><div><h3>Interpretation</h3><div>Pramipexole augmentation for TRD has demonstrated both clinical and cost-effectiveness. Further trials, directly comparing pramipexole to other augmentation strategies, will be useful in determining the position of this repurposed medication in the treatment pathway of depression.</div></div><div><h3>Funding</h3><div><span>National Institute for Health and Care Research</span>, <span>Efficacy and Mechanism Evaluation Programme</span>.</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"61 ","pages":"Article 101533"},"PeriodicalIF":13.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145580503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of an environmental nutrition and physical activity intervention in early childhood education and care settings (NAPSACC UK): a multicentre cluster randomised controlled trial","authors":"Ruth Kipping ,&nbsp;Sharon Anne Simpson ,&nbsp;Kim Hannam ,&nbsp;Peter S. Blair ,&nbsp;Russell Jago ,&nbsp;Corby K. Martin ,&nbsp;Zoi Toumpakari ,&nbsp;Laura Johnson ,&nbsp;James Garbutt ,&nbsp;Rachel Maishman ,&nbsp;James White ,&nbsp;Rebecca Langford ,&nbsp;William Hollingworth ,&nbsp;Madeleine Cochrane ,&nbsp;Laurence Moore ,&nbsp;Chris Metcalfe ,&nbsp;Anne Martin ,&nbsp;Stephanie Chambers ,&nbsp;Thomas Reid ,&nbsp;Megan Pardoe ,&nbsp;Miranda Pallan","doi":"10.1016/j.lanepe.2025.101550","DOIUrl":"10.1016/j.lanepe.2025.101550","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;Early childhood education and care (ECEC) provision is widespread. NAPSACC UK is an intervention in ECECs designed to improve nutrition and physical activity policies, practice and provision through ECEC staff workshops, self-assessment and assistance over one year. It was adapted for the UK from the USA and we tested whether it reduced energy consumption and increased physical activity.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;Repeated cross-sectional, multicentre, two-arm, single-blind, parallel-group, cluster-randomised controlled trial including ECEC providers in the UK. The randomisation was conducted by a statistician who was blinded to ECEC provider identity, with allocation within each local authority area and by ECEC Index of Multiple Deprivation scores to minimise differences between arms. Participants were not blind to allocation. Co-primary outcomes after 12-months were child average total energy consumed per eating occasion in the ECEC (lunch or snack) and child accelerometer-assessed total physical activity on ECEC days. Secondary outcomes were moderate-to-vigorous physical activity, sedentary time, energy served and consumed at lunch and snacks, diet quality, and Body Mass Index z-score. The senior statistician and majority of co-investigators were blinded. Analysis was intention-to-treat. Trial registration is ISRCTN33134697 and is completed.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Findings&lt;/h3&gt;&lt;div&gt;Between 14 March 2022 and 25 March 2024 we enrolled 52 ECEC providers (25 intervention; 27 control) and 835 2-5 year-olds (401 intervention, 434 control). The co-primary outcomes were assessed 12 months after baseline with data provided by 382 children for nutrition and 244 children for physical activity. There was no evidence of a difference in the co-primary outcomes compared to control of average kcal per eating occasion in ECEC (adjusted geometric mean ratio 0.86 (95% CI 0.72–1.03; p = 0.09)) or total physical activity (adjusted mean difference (aMD) −2.13 min (95% CI −10.96 to 6.70; p = 0.64)). There was evidence of lower lunch energy served (aMD −69.1 kcal per occasion (95% CI −116 to −22.2; p = 0.004)) and consumed (aMD −67.7 kcal per occasion (95% CI −118.6 to −18.7, p = 0.009)) with the intervention. There was no evidence of differences in other secondary outcomes. No adverse events were reported.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Interpretation&lt;/h3&gt;&lt;div&gt;NAPSACC UK did not improve average kcal per eating occasion in ECEC or physical activity. Lower lunch energy servings and consumption closer to recommendations were observed as secondary outcomes. The lower fidelity to the intervention than intended and staffing pressures give insight into interpretation of the null result. Therefore, we recommend that policy-level and statutory changes, which require low agency by individual ECEC settings are research and policy priorities for nutrition and physical activity in ECEC.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Funding&lt;/h3&gt;&lt;div&gt;&lt;span&gt;National Institute for He","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"61 ","pages":"Article 101550"},"PeriodicalIF":13.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146144557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary endpoint acceptance is strongly associated with a positive benefit assessment: a self-fulfilling prophecy","authors":"Charalabos-Markos Dintsios","doi":"10.1016/j.lanepe.2025.101577","DOIUrl":"10.1016/j.lanepe.2025.101577","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"61 ","pages":"Article 101577"},"PeriodicalIF":13.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145883338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Work ability trajectories and sick leave in individuals with post COVID-19 condition: 3-year follow-up of a population-based cohort","authors":"Tala Ballouz,&nbsp;Philipp Kerksieck,&nbsp;Sarah R. Haile,&nbsp;Holger Dressel,&nbsp;Oliver Hämmig,&nbsp;Georg F. Bauer,&nbsp;Jan S. Fehr,&nbsp;Milo A. Puhan,&nbsp;Dominik Menges","doi":"10.1016/j.lanepe.2025.101536","DOIUrl":"10.1016/j.lanepe.2025.101536","url":null,"abstract":"<div><h3>Background</h3><div>Data on the longer-term impact of post COVID-19 condition (PCC) on work-related functioning is limited, despite evidence on the persistence of PCC for years after infection. This study aimed to describe changes in work ability and sick leave associated with PCC up to three years post-infection.</div></div><div><h3>Methods</h3><div>We used data from 667 working-age individuals within a prospective population-based cohort following individuals infected with SARS-CoV-2 between August 2020 and January 2021. PCC was determined at 12 months and work ability was assessed biannually. The impact of SARS-CoV-2 on participants’ physical and mental work performance and COVID-19 related sick leave were assessed at three years.</div></div><div><h3>Findings</h3><div>Participants with protracted COVID-19 related symptoms at 12 months after infection reported persistently lower work ability scores than those without symptoms, with no evidence of a difference in change over time (−0.12 points per year, 95% CI −0.29 to 0.07). Compared to recovered individuals, work ability scores among those with moderate health impairment improved by +0.72 points per year (95% CI −0.04 to 1.46), while trends were similar among those with mild or severe impairment. A higher proportion of participants with PCC reported worsening in physical and mental performance at work than those without PCC. Among those with PCC, 11.5% (9/78) reported taking COVID-19 related sick leave for one month or more, in contrast to 4.0% (13/327) among those without PCC.</div></div><div><h3>Interpretation</h3><div>The study highlights the prolonged impact of PCC on work-related functioning and underscores the need for targeted occupational, clinical and social measures for those affected.</div></div><div><h3>Funding</h3><div><span>Federal Office of Public Health</span>, <span>Department of Health of the Canton of Zurich</span>, <span>University of Zurich Foundation</span>, Switzerland; <span>Horizon Europe</span>.</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"61 ","pages":"Article 101536"},"PeriodicalIF":13.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145580504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A multimodal individualized long-term intervention to prevent functional decline after stroke (LAST-long): a single blinded randomised controlled trial","authors":"Torunn Askim ,&nbsp;Sara Rise Langlo ,&nbsp;Elin Bergh ,&nbsp;Øystein Døhl ,&nbsp;Hanne Ellekjær ,&nbsp;Anne Hokstad ,&nbsp;Håkon Ihle-Hansen ,&nbsp;Bent Indredavik ,&nbsp;Stian Lydersen ,&nbsp;Geske Luzum ,&nbsp;Yngve Seljeseth ,&nbsp;Toril Skandsen ,&nbsp;Ingvild Saltvedt ,&nbsp;Bente Thommessen","doi":"10.1016/j.lanepe.2025.101531","DOIUrl":"10.1016/j.lanepe.2025.101531","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;Despite the lack of evidence, the Stroke Action Plan for Europe recommends coordinated support after initial rehabilitation. This trial investigated if a coordinator-led multimodal intervention was superior to standard care in preventing dependency and functional decline after stroke.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;In this single blinded randomised controlled multi-centre trial, patients were consecutively screened, included and randomised (1:1) by a web-based randomization system to an intervention or a control group at the out-patient clinics at four Norwegian hospitals three months post-stroke. Blinded assessments were performed at inclusion and at 6-, 12-, and 18-month follow-up. The inclusion criteria were; age ≥18 years, life expectancy ≥12 months (assessed by the physician), modified Rankin Scale (mRS) score &lt;5, vulnerable to functional decline (defined by other measures). The control group received standard care, while the intervention group additionally received monthly follow-up by a community-based stroke coordinator who applied a study specific checklist to identify the patients’ risk profile within multiple domains. Individual goals and action points were defined accordingly. The intervention lasted for 18 months. Mixed models were used to evaluate differences between the groups for the primary endpoint (mRS at 18-month follow-up) and secondary endpoints (activities of daily living, cognitive function, physical function, patient reported outcomes, physical activity, blood pressure, body mass index and blood tests) at 6-, 12-, and 18-month follow-up. The trial was registered at ClinicalTrials.gov identifier: NCT03859063. The trial has been completed.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Findings&lt;/h3&gt;&lt;div&gt;The LAST-long trial was conducted from April 11, 2019 to August 28, 2024. In total, 301 participants (48% women); mean age 71·3 (SD 12·3) years, National Institute of Health Stroke Scale admission score 3·38 (SD 4·21), and mRS at inclusion 1·6 (SD 0·9), were randomised to the intervention (n = 152) or control (n = 149) group 108.0 (SD 18·5) days post stroke. The number of serious adverse events (deaths, hospitalisation due to cardiovascular events, cerebrovascular events or fall with or without fracture) was 32 (21·1%) in the intervention group and 33 (22·1%) in the control group. At 18 months, the estimated difference between the groups was 0·03 (95% CI: −0·16 to 0·22), p = 0·79 for mRS.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Interpretation&lt;/h3&gt;&lt;div&gt;The 18-month multimodal intervention was not superior to standard care received by the control group in people with mild stroke. An even longer follow-up period might be needed to investigate the effect of the intervention on hard outcomes like death or recurrent vascular events.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Funding&lt;/h3&gt;&lt;div&gt;The Research Council of Norway, The Joint Research Committee between St. Olavs Hospital and the Faculty of Medicine and Health Sciences, NTNU (FFU), Foundation Dam.&lt;/div&gt;&lt;/d","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"61 ","pages":"Article 101531"},"PeriodicalIF":13.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145499917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Viral infections and invasive group A streptococcal disease incidence during 2022–2023 – authors' reply","authors":"Léa Lenglart ,&nbsp;Izel Özmen ,&nbsp;Ruud G. Nijman ,&nbsp;Naïm Ouldali ,&nbsp;Dorine Borensztajn","doi":"10.1016/j.lanepe.2025.101583","DOIUrl":"10.1016/j.lanepe.2025.101583","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"61 ","pages":"Article 101583"},"PeriodicalIF":13.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145938539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thank you to The Lancet Regional Health – Europe's clinical and statistical peer reviewers in 2025","authors":"Pooja Jha,&nbsp;Ivana Nedic,&nbsp;Stephanie Becker,&nbsp;Anna Johnson","doi":"10.1016/j.lanepe.2026.101608","DOIUrl":"10.1016/j.lanepe.2026.101608","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"61 ","pages":"Article 101608"},"PeriodicalIF":13.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146187306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}